Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cisco Systems Inc (CSCO) vs Cassava Sciences Inc (FLNA) Price & Performance

Cisco Systems IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Cisco Systems Inc vs Cassava Sciences Inc — how do they compare? Cisco Systems Inc trades at $123.05 (market cap $474.67B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Cisco Systems Inc is far larger — about 9940.7× Cassava Sciences Inc's market cap, and Cisco Systems Inc pays a 1.4% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

CSCOFLNA
Market Cap
$474.67B$47.75M
Volume
22,887,319
Sector
TechnologyHealth
52-Week High
$130.00$4.64
52-Week Low
$66.20$0.87
Enterprise Value
$489.33B-$34.93M
Dividend Yield
1.4%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cisco Systems Inc

Cisco Systems (CSCO) trades at $122.57, up 0.94% today, near its recent highs driven by strong AI cybersecurity momentum. The stock shows bullish technical signals with moving averages supporting the uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, CSCO reported revenue of $56.65B in 2025 with a net income margin of 19.69%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights partnerships and product launches in AI security, fueling investor optimism.

CSCO's outlook is positive with a consensus price target of $133.25, implying ~9% upside, supported by 52% analyst buy ratings. Key opportunities include growth in AI-driven networking and security demand, but risks involve high valuation multiples (P/E 40.14) and competitive pressures in the tech sector. Investors should weigh strong cash flow generation against execution risks in a dynamic market.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cisco Systems Inc

Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.

Read more on CSCO

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA